Skip to main content
. Author manuscript; available in PMC: 2015 Aug 26.
Published in final edited form as: J Alzheimers Dis. 2009;16(4):705–714. doi: 10.3233/JAD-2009-0983

Fig. 4.

Fig. 4

Ceramide treatment modulates neuronal indices of AD-type neurodegeneration. PNET2 cells were treated with vehicle or 15.7 µM C6, or C2D ceramide for 48 h. Protein homogenates were used to measure (A) 4-hydroxynonenol-4-HNE; B) ubiquitin; (C) GAPDH; (D) β-actin; (E) acetylcholinesterase (AChE); and (F) choline acetyltransferase (ChAT) by direct ELISA (see Materials and Methods). Immunoreactivity was detected with HRP-conjugated secondary antibody and Amplex Red soluble fluorophor. Fluorescence light units (FLU) were measured (Ex 579 nm/Em 595 nm) in a Spectromax M5. Graphs depict mean ± S.E.M of results (N = 6 samples per group). Inter-group comparisons were made using one-way ANOVA with the post-hoc Dunn’s multiple comparison test of significance relative to vehicle-treated controls. Significant P-values are indicated within the panels.